When to Switch to More Efficacious Agents

EP: 1.Impact of First-Line Therapy on Long-Term Outcomes in nAMD and DME

EP: 2.Choosing First-Line Therapy in nAMD or DME

Now Viewing

EP: 3.When to Switch to More Efficacious Agents

EP: 4.Real-World Experiences With Faricimab

EP: 5.Real-World Experiences With Aflibercept 8mg

EP: 6.Efficacy and Durability: New Therapies vs Aflibercept 2mg

EP: 7.Perspectives on Retinal Fluid Management

EP: 8.Perspectives on Loading Dose Recommendations for New Therapies

EP: 9.Safety Considerations for New Therapies

EP: 10.The Impact of Biosimilars in Retinal Diseases

EP: 11.The Status of Gene Therapy Development for Retinal Diseases

EP: 12.Considering Safety of Gene Therapy for Retinal Diseases

EP: 13.Role of Tyrosine Kinase Inhibitors and Gene Therapy in Retinal Diseases

EP: 14.Perspectives on the Future of Retinal Disease Management

Summary

Experts discuss the strategy of switching patients to more efficacious, second-generation agents like aflibercept 8 milligrams or faricimab. Eichenbaum emphasizes his preference for swift transitioning to these second-generation therapies, considering them more potent and durable. He inquires whether the other panelists share a similar approach or if they prefer a more gradual transition, reserving the more potent agents as a last resort. Kenneth Fan, MD, MBA expresses a preference for an aggressive approach, aiming to start with aflibercept 8 milligrams or faricimab to achieve better long-term outcomes. He advocates for personalized treatment plans, emphasizing a clear and rationale reason for switching therapies based on anatomical and visual responses. The trials, such as PULSAR and PHOTON, have contributed significant insights into treatment intervals and dose modifications. Fan, MD, MBA underscores the importance of communicating these decisions transparently to patients, ensuring they understand the rationale behind the switch.

This summary was AI-generated and edited for clarity.